Market Overview
Genetic tests are medical instruments that come in the form of kits or panels and are used to diagnose genetic illnesses in people. Furthermore, blood samples from patients are collected throughout the exam. These samples are then tested utilizing test kits on laboratory equipment. Measurement of the results of genetic alterations, such as RNA analysis as an output of gene expression, or biochemical analysis to quantify particular protein production, are examples of genetic testing. Numerous sorts of tests are utilized to diagnose genetic abnormalities. Predictive testing, carrier testing, prenatal and neonatal testing, diagnostic testing, pharmacogenomic testing, nutrigenomics, and other genetic tests are available to detect diseases. Newborn testing, for example, can detect genetic diseases early in life, allowing treatment to begin as soon as feasible. In addition, these tests are utilized to diagnose medical disorders such as cancer, hereditary disorders, and cardiovascular disease.

Genetic testing market: Key Players
Abbott Laboratories
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Bio-Rad Laboratories Inc.
Myriad Genetics, Inc. (Myriad RBM, Inc.)
Danaher Corporation (Cepheid)
F. Hoffmann-La Roche AG
Eurofins Scientific
Illumina Inc.
Thermo Fisher Scientific
Danaher Corporation (Cepheid Inc)
RainDance Technologies Inc.

Growth Factor
Genetic testing for Cancer cure
According to the World Health Organization, cancer led to the deaths of 9.6 million people globally in 2018. These figures are concerning since the illness is at an all-time high, impacting the whole planet and bordering on epidemic proportions. Breast cancer, ovarian cancer, bowel cancer, womb cancer, and prostate cancer can all be diagnosed quickly thanks to genetic testing. A family history of cancer is required for genetic testing and assistance in the prevention of this devastating illness. This application sector was one of the most popular in the genetic testing market, and it is predicted to continue to develop gradually in future.

Segmentation
By Types of Testing
Newborn Screening
Diagnostic Testing
Carrier Testing
Prenatal Testing
Forensic Testing
Predictive and Presymptomatic Testing
Others
By Methods
Molecular Genetic Testing
Chromosomal Genetic Testing
Biochemical Genetic Testing
Others
By Testing Sample
Blood
Saliva
Hair
Tumors
Others
By Industry
Laboratories
Blood Banks
Nursing Homes
Hospitals
Others
Genetic Testing Market Dynamics
Genetic Testing Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints

Recent News Related to Market
The FDA extended the approval of a cancer blood test called “liquid biopsy” in November 2020, which identifies genetic changes in tumor DNA in the blood and can assist match patients to prospective therapies.
In August 2020, Guardant360 CDx of Guardant Health and FoundationOne Liquid CDx of Foundation Medicine were authorized by the FDA for use as a companion diagnostic test and for general tumor profiling.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
COVID-19 pre and post business impact analysis
Detailed overview of the parent market
Changing market dynamics in the industry
In-depth market segmentation
What is the Genetic testing market growth?
Which segment accounted for the largest Genetic testing market share?
Who are the key players in the Genetic testing market?
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint

Note: Although care has been taken to maintain the highest levels of accuracy in Our reports, recent market/vendor-specific changes may take time to reflect in the analysis.

The post Global Genetic Testing Market Market Outlook 2030: Industry Insights & Opportunity Evaluation, 2019-2030 first appeared on CRI Report.

Market Segmentation

• Product Type – Products (Kits and Assays, Instruments, and Software) and Services
• Sample– Tissue-Based, Blood-Based, Bone Marrow Aspirates, and Others
• Technology – Sequencing (NGS and Traditional Sequencing), Polymerase Chain Reaction (RT-PCR and dPCR), Microarray, and Other Technologies
• Application – Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Liver Cancer, Ovarian Cancer, and Other Solid Tumors), and Hematological Malignancies (Leukemia, Lymphoma, and Myeloma)
• End User – Academic and Research Institutions, Hospitals and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Other End Users

Regional Segmentation

• North America – U.S., and Canada
• Europe – Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, Australia, South Korea, and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World

Growth Drivers

• Global Increase in Cancer Prevalence
• Increasing Consumer Awareness for Tailored Cancer Therapy
• Decreasing Cost of Sequencing
• Increasing Adoption of Inorganic Growth Strategies in the Market

Market Challenges

• Uncertain Regulatory and Reimbursement Policies
• Lack of Trained Professionals in the Field of Oncology
• Lack of Established Treatment Protocols for High-Valued Cancer Tests in Emerging Economies

Market Opportunities

• Technological Advancements in the Field of Cancer Genomics
• Massive Scope for Adoption of NGS-based Somatic Genetic Testing in the Emerging Markets

Key Companies Profiled

Agilent Technologies, Inc., ARUP Laboratories, ASURAGEN INC., Beijing Genomics Institute (BGI) Genomics Co., Ltd, bioMérieux S.A., CENTOGENE N.V, CIRCULOGENE Theranostics, LLC, F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Mission Bio, NeoGenomics Laboratories, Inc., OmniSeq, Oxford Nanopore Technologies, Ltd., Pacific Biosciences of California, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, and Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

• How is somatic genetic testing revolutionizing the field of cancer diagnostics?
• What are the major market drivers, challenges, and opportunities in the global somatic genetic testing market?
• What are the underlying structures resulting in the emerging trends within the global somatic genetic testing market?
• How did the COVID-19 pandemic impact the global somatic genetic testing landscape?
• What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to somatic genetic testing?
• What are the potential entry barriers, which are expected to be faced by the companies willing to enter in a particular region?
• How is each segment of the market expected to grow during the forecast period from 2020 to 2030 and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o Product Type (Products and Services)
o Sample (Tissue-Based, Blood-Based, Bone Marrow Aspirates, and Others)
o Technology (Sequencing, PCR, Microarray, and Others)
o Application (Solid Tumors and Hematological Malignancies)
o End User (Academic and Research Institutions, Hospitals and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Others)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the companies in the region of their operation?
• Who are the leading players with significant offerings in the global somatic genetic testing market?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the current unmet needs that are being faced?

Market Overview

Our healthcare experts have found somatic genetic testing industry to be one of the most rapidly evolving and dynamic markets and the global market for somatic genetic testing is predicted to grow at a CAGR of 9.30% over the forecast period of 2020-2030. The market is driven by certain factors, which include, global increase in cancer prevalence, increasing consumer awareness for tailored cancer therapies, decreasing cost of sequencing, and increasing adoption of inorganic growth strategies in the market.

The market is favored by the developments in the field of cancer genomics and its attributes such as somatic mutation analysis. The global somatic genetic testing is witnessing significant growth due to the increase in cancer prevalence, increasing consumer awareness for tailored cancer therapy, decreasing cost of sequencing, and increasing adoption of inorganic growth strategies in the market. Additionally, rapid adoption of sequencing instruments by the researchers to conduct cancer genomic research and increasing emphasis on precision medicine are some of the critical factors, which are expected to bolster the market growth.

Furthermore, biotechnology companies are focusing on the development of robust somatic genetic testing solutions for a wide range of applications to support clinicians for conducting in-depth somatic mutation analysis.

Within the research report, the market is segmented on the basis of product type, sample, technology, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of cases associated with cancer has created a buzz among the biotechnology companies, compelling them to further invest in the development of cancer diagnostic solutions for somatic mutation analysis, thereby aiding clinicians to offer precision therapeutics for cancer treatment. Due to the presence of a diverse product portfolio and intense market penetration, Thermo Fisher Scientific Inc. has been a pioneer in this field and has been a significant competitor in this market.

On the basis of region, North America holds the largest share of the somatic genetic testing market due to high infusion of funding from the government organizations for conducting cancer research, growing prevalence of cancer, rising awareness about precision medicine, and increasing awareness about early cancer detection, among others. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2020-2030.

The post Global Somatic Genetic Testing Market: Focus on Product Type, Sample, Technology, Applications, End Users, Country Data (15 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2030 first appeared on CRI Report.